• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Evernorth Launches New Benefit Option That Drives Lower Net Cost for Weight Loss Medicines and Limits Patient Cost to No More Than $200 Per Month

    5/21/25 4:30:00 PM ET
    $CI
    Medical Specialities
    Health Care
    Get the next $CI alert in real time by email
    • Patients can save as much as $3600 per year versus direct-to-consumer manufacturer programs, and out of pocket cost applies to their annual deductible
    • New offering helps employers meet growing demand for FDA-approved weight loss medications at a lower net cost per prescription while ensuring clinical safety for patients

    ST LOUIS, May 21, 2025  /PRNewswire/ -- Evernorth, the health services division of The Cigna Group (NYSE:CI) announced a first-of-its-kind pharmacy benefit offering that make weight loss medications WEGOVY® and ZEPBOUND® more available to patients. Through direct negotiations with the medications' manufacturers, Evernorth has ensured that patients' monthly cost will not exceed $200.

    Evernorth Health Services (PRNewsfoto/Evernorth Health Services)

    "We are reimagining pharmacy benefits to reduce costs and better serve patients," said Adam Kautzner, Pharm D, President of Evernorth Care Management and Express Scripts. "This is what Express Scripts does better than anyone: save Americans money on their prescriptions while helping them achieve their health goals." 

    This initiative fills a critical need in the market by offering savings, choice and predictability to both patients and health plan sponsors.

    Benefits for Patients:

    • Lower Monthly Copays than Cash Programs: The monthly copay for GLP-1 weight loss medicines will be limited to no more than $200, which will have the added benefit of counting towards the patient's annual deductible.
    • Meaningful Savings: Patients can save as much as $3,600 per year compared to buying these medications directly from manufacturers or through consumer programs.
    • Enhanced Safety and Efficacy: By accessing WEGOVY® or ZEPBOUND® through Evernorth's pharmacy benefit, patients will benefit from FDA-approved medications and Express Scripts' robust safety checks designed to reduce negative or adverse drug interactions.
    • Simplified Approval and Access: The prior authorization processes accompanying the new offering will be simplified and automated for faster access.
    • Choice of Pharmacies: Patients can select from a broad network of local retail pharmacies or home delivery through Evernorth's EnGuide Pharmacy, staffed by clinicians with specialized knowledge in GLP-1s for enhanced support.

    Benefits for Employers & Other Health Plan Sponsors:

    • Significant Cost Reduction: Health plan sponsors will see a significant reduction in the net cost per prescription of GLP-1 medications.
    • Offering Patient Options: Health plan sponsors can ensure that patients have access to the medication that works best for them, without compromising affordability or clinical safety.

    "As advocates for the millions of people we serve, we drive lower medication costs through negotiations with the pharmaceutical manufacturers, and we're making it easier than ever for health plan sponsors to cover GLP-1s for weight loss," said Harold Carter, PharmD, senior vice president of trade relations at Express Scripts. "This is how we deliver on our promise to put patients first - by making innovative medicines more accessible, at a lower cost, while providing patients and physicians choices in this fast-evolving market."

    Evernorth has the most extensive suite of GLP-1 solutions available with this new addition, which also includes:

    • EncircleRx, a financial model with more than 9 million enrolled lives that has saved health plans $200 million dollars since 2024.
    • EnReachRx, a high-touch patient support clinical model for dispensing GLP-1 prescription medications.

    About Evernorth Health Services

    Evernorth Health Services creates pharmacy, care, and benefits solutions to improve health and increase vitality. We relentlessly innovate to make the prediction, prevention, and treatment of illness and disease more accessible to millions of people. Evernorth capabilities are powered by our businesses, including Express Scripts, Express Scripts® Pharmacy, Accredo, eviCore, and MDLIVE, along with holistic Evernorth platforms and solutions that move people and organizations forward. All Evernorth solutions are serviced and provided by or through operating affiliates of Evernorth Health, a wholly owned subsidiary of The Cigna Group (NYSE:CI), or third-party partners. Learn more at evernorth.com.

    Media Contact:

    Justine Sessions

    [email protected]

    860-810-6523

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/evernorth-launches-new-benefit-option-that-drives-lower-net-cost-for-weight-loss-medicines-and-limits-patient-cost-to-no-more-than-200-per-month-302462363.html

    SOURCE Evernorth

    Get the next $CI alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CI

    DatePrice TargetRatingAnalyst
    2/6/2025$323.00Outperform → Mkt Perform
    Bernstein
    6/26/2024$400.00Overweight
    Piper Sandler
    5/30/2024$388.00Outperform
    Robert W. Baird
    3/6/2024$393.00Overweight
    Barclays
    2/5/2024$334.00 → $372.00Neutral → Overweight
    Cantor Fitzgerald
    2/5/2024$327.00 → $354.00Sector Perform → Outperform
    RBC Capital Mkts
    2/1/2024$355.00 → $370.00Hold → Buy
    Deutsche Bank
    1/4/2024$330.00 → $372.00Mkt Perform → Outperform
    Bernstein
    More analyst ratings

    $CI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • The Cigna Group downgraded by Bernstein with a new price target

      Bernstein downgraded The Cigna Group from Outperform to Mkt Perform and set a new price target of $323.00

      2/6/25 7:05:01 AM ET
      $CI
      Medical Specialities
      Health Care
    • Piper Sandler initiated coverage on The Cigna Group with a new price target

      Piper Sandler initiated coverage of The Cigna Group with a rating of Overweight and set a new price target of $400.00

      6/26/24 7:28:18 AM ET
      $CI
      Medical Specialities
      Health Care
    • Robert W. Baird initiated coverage on The Cigna Group with a new price target

      Robert W. Baird initiated coverage of The Cigna Group with a rating of Outperform and set a new price target of $388.00

      5/30/24 7:35:19 AM ET
      $CI
      Medical Specialities
      Health Care

    $CI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hennigan Michael J was granted 568 shares (SEC Form 4)

      4 - Cigna Group (0001739940) (Issuer)

      6/4/25 4:58:29 PM ET
      $CI
      Medical Specialities
      Health Care
    • SEC Form 3 filed by new insider Hennigan Michael J

      3 - Cigna Group (0001739940) (Issuer)

      6/3/25 5:04:45 PM ET
      $CI
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Kurian George

      4 - Cigna Group (0001739940) (Issuer)

      6/3/25 5:04:40 PM ET
      $CI
      Medical Specialities
      Health Care

    $CI
    Financials

    Live finance-specific insights

    See more
    • The Cigna Group's Second Quarter 2025 Earnings Release Details

      BLOOMFIELD, Conn., June 25, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) will release its second quarter 2025 financial results on Thursday, July 31, 2025, and will host a conference call the same day. Second quarter 2025 financial results will be released no later than 6:30 a.m. Eastern Time (ET). Management will review these results on a conference call beginning at 8:30 a.m. ET. The call-in numbers are as follows: Live Call(888) 566-1889 (Domestic)(773) 799-3989 (International)Passcode: 07312025 Replay(800) 835-8067 (Domestic)(203) 369-3354 (Internat

      6/25/25 8:00:00 AM ET
      $CI
      Medical Specialities
      Health Care
    • The Cigna Group Reports Strong First Quarter 2025 Results, Raises 2025 Outlook

      Total revenues for the first quarter 2025 increased 14% to $65.5 billionShareholders' net income for the first quarter 2025 was $1.3 billion, or $4.85 per shareAdjusted income from operations1 for the first quarter 2025 was $1.8 billion, or $6.74 per share2025 adjusted income from operations1,2 increased to at least $29.60 per share2BLOOMFIELD, Conn., May 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) today reported strong first quarter 2025 results, reflecting growth and focused execution across its diversified portfolio of businesses. "We are buildin

      5/2/25 6:00:00 AM ET
      $CI
      Medical Specialities
      Health Care
    • The Cigna Group Declares Quarterly Dividend

      BLOOMFIELD, Conn., April 23, 2025 /PRNewswire/ -- The Board of Directors of The Cigna Group (NYSE:CI) today declared a cash dividend of $1.51 per share of its common stock, payable on June 18, 2025 to shareholders of record as of the close of business on June 3, 2025. About The Cigna Group The Cigna Group (NYSE:CI) is a global health company committed to creating a better future built on the vitality of every individual and every community. We relentlessly challenge ourselves to partner and innovate solutions for better health. The Cigna Group includes products and services m

      4/23/25 4:30:00 PM ET
      $CI
      Medical Specialities
      Health Care

    $CI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Healthcare's $110B AI Surge Is Picking Up Speed--and It's Just the Beginning

      USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- As artificial intelligence reshapes the future of medicine, understanding how patients actually feel about it is becoming just as critical as the technology itself. A new study published in Nature introduced an "AI Affinity Score" to measure patient comfort with AI in clinical settings—showing that education level and region heavily influence acceptance. The findings suggest that personalizing AI integration based on patient attitudes can enhance care quality and satisfaction. That kind of insight is already guiding investor attention toward emerging opportunities in a secto

      7/8/25 9:34:00 AM ET
      $CI
      $GEHC
      $IQV
      $WAY
      Medical Specialities
      Health Care
      Medical Electronics
      Biotechnology: Commercial Physical & Biological Resarch
    • The Cigna Group Foundation Addresses Mental Health and Housing Stability for Veterans with $3 Million in Grants

      Nonprofits are encouraged to apply now for 2025 fundingThe Cigna Group Foundation committed $9 million in 2024 to address veteran mental health, distributing $3 million each year through 2026In first year, 23 grantees were awarded grants to help local veterans feel stable where they live, create positive impact on their mental healthBLOOMFIELD, Conn., July 8, 2025 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE:CI), announced today a new round of grants aimed at improving the mental health of military veterans. As part of a $9 million, three-year commitment that began in 2024, this latest funding focuses on nonprofits working to address the signific

      7/8/25 6:00:00 AM ET
      $CI
      Medical Specialities
      Health Care
    • The Cigna Group Foundation Announces Grants to 24 Nonprofits, Builds on Momentum to Help Address Youth Mental Health Crisis

      BLOOMFIELD, Conn., June 30, 2025 /PRNewswire/ -- The Cigna Group Foundation, the philanthropic arm of The Cigna Group (NYSE:CI), today announced its second round of grant recipients supporting youth mental health. As part of this grant program, The Cigna Group Foundation has allocated $9 million to nonprofit organizations over three years to positively impact the youth mental health crisis. "Our kids and teens across the United States continue to struggle with mental health issues in the post-pandemic world, so it's essential that we build on the positive momentum set forth by our first grantee cohort in improving youth mental health," said Melissa Skottegaard, board chair, The Cigna Group

      6/30/25 6:00:00 AM ET
      $CI
      Medical Specialities
      Health Care

    $CI
    Leadership Updates

    Live Leadership Updates

    See more
    • The Cigna Group Announces Appointment of Michael J. Hennigan to Board of Directors

      BLOOMFIELD, Conn., June 2, 2025 /PRNewswire/ -- Global health company The Cigna Group (NYSE:CI) announced today that Michael J. Hennigan has been appointed to the organization's Board of Directors. His appointment is effective June 2. Mr. Hennigan is the Executive Chairman of Marathon Petroleum Corporation (MPC), an integrated downstream energy company, and MPLX, a diversified master limited partnership formed by MPC. He joined the company in 2017 and previously held the roles of Chief Executive Officer of MPC and Chairman, President and Chief Executive Officer of MPLX. Prior

      6/2/25 4:30:00 PM ET
      $CI
      Medical Specialities
      Health Care
    • The Cigna Group's "Community Vitality Project" Donates $75,000 to Nonprofits through Program Encouraging Fitness and Community Engagement

      As part of the company's initiative, thousands of employees logged 280,000 minutes of exercise over nine days Cigna leaders biked to Hartford, Conn.'s Dunkin' Park to host Boys & Girls Clubs members for a Yard Goats baseball game, with surprise appearances by UConn basketball coach and playersBLOOMFIELD, Conn., Sept. 9, 2024 /PRNewswire/ -- The Cigna Group (NYSE:CI) put out a challenge to its workforce this summer, inviting colleagues to join its first-ever Community Vitality Project, a nine-day challenge combining fun, fitness and fundraising. By logging more than 280,000 minutes of fitness activities and awarding their minutes spent moving, The Cigna Group employees helped determine how to

      9/9/24 7:00:00 AM ET
      $CI
      Medical Specialities
      Health Care
    • The Cigna Group announces leadership changes to continue driving growth

      Brian Evanko to continue as Chief Financial Officer, will serve as new President and CEO of Cigna HealthcareAnn Dennison to join The Cigna Group as Deputy Chief Financial OfficerMike Triplett to retire by end of 2024 and Bryan Holgerson promoted to President of U.S. Commercial for Cigna HealthcareEric Palmer to assume expanded role leading enterprise strategy and corporate development, will continue as President and CEO of Evernorth Health ServicesBLOOMFIELD, Conn., Jan. 17, 2024 /PRNewswire/ -- The Cigna Group (NYSE:CI), a global health company, today announced leadership changes designed to continue accelerating growth across Evernorth Health Services and Cigna Healthcare.

      1/17/24 9:15:00 AM ET
      $CI
      Medical Specialities
      Health Care

    $CI
    SEC Filings

    See more
    • SEC Form 11-K filed by The Cigna Group

      11-K - Cigna Group (0001739940) (Filer)

      6/27/25 4:23:33 PM ET
      $CI
      Medical Specialities
      Health Care
    • The Cigna Group filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Cigna Group (0001739940) (Filer)

      6/2/25 5:03:47 PM ET
      $CI
      Medical Specialities
      Health Care
    • The Cigna Group filed SEC Form 8-K: Regulation FD Disclosure

      8-K - Cigna Group (0001739940) (Filer)

      5/20/25 6:01:22 AM ET
      $CI
      Medical Specialities
      Health Care

    $CI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by The Cigna Group

      SC 13G - Cigna Group (0001739940) (Subject)

      11/12/24 9:55:14 AM ET
      $CI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by The Cigna Group (Amendment)

      SC 13G/A - Cigna Group (0001739940) (Subject)

      2/13/24 5:02:29 PM ET
      $CI
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by The Cigna Group (Amendment)

      SC 13G/A - Cigna Group (0001739940) (Subject)

      2/9/24 8:50:20 AM ET
      $CI
      Medical Specialities
      Health Care